Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
Tevogen Bio Holdings Inc. (TVGN)
Company Research
Source: GlobeNewswire
Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of patient inquiries, Tevogen has established a dedicated communication channel for Long COVID updates at longCOVID@tevogen.com WARREN, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today issued an update regarding growing public interest in its investigational precision T cell therapy, TVGN 489, under development for COVID-19 and Long COVID. “We’re deeply moved by the number of Long COVID patients expressing interest in TVGN 489,” said Dr. Ryan Saadi, Chief Executive Officer of Tevogen Bio. “This level of engagement underscores the urgent need for effective and durable solutions. Our team remains fully committed to advancing this science with both urgency and care.” The Company’s dose-finding clinical trial of TVGN
Show less
Read more
Impact Snapshot
Event Time:
TVGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVGN alerts
High impacting Tevogen Bio Holdings Inc. news events
Weekly update
A roundup of the hottest topics
TVGN
News
- Tevogen Bio (NASDAQ:TVGN) had its price target lowered by analysts at D. Boral Capital from $10.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q [Yahoo! Finance]Yahoo! Finance
- Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-QGlobeNewswire
- Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVIDGlobeNewswire
- Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash BurnGlobeNewswire
TVGN
Sec Filings
- 11/14/25 - Form 424B3
- 11/14/25 - Form 10-Q
- 9/26/25 - Form 424B3
- TVGN's page on the SEC website